Annexon, Inc.

Annexon, Inc. (ANNX) priced its initial public offering on Jul 24, 2020 at $17.00 per share, above its $15.00–$16.00 range, raising $250.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $612.1M. J.P. Morgan was lead-left underwriter, joined by BofA Securities and TD Cowen. Latham & Watkins advised the company and Cooley advised the underwriters.

Annexon, Inc. is a clinical-stage biopharmaceutical company developing therapies for classical complement-mediated disorders of the body, brain and eye. Its platform inhibits C1q, the molecule that starts the classical complement pathway, to address autoimmune and neurodegenerative disease processes.

Status

IPO

Ticker

ANNX

Exchange

Nasdaq Global Select

Priced

Jul 24, 2020

IPO price

$17.00

Price range

$15.00–$16.00

Raised

$250.8M

Market cap at IPO price

$612.1M

First filed

Jul 2, 2020

Underwriters

J.P. Morgan, BofA Securities and TD Cowen

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.